Patents by Inventor Matthias Michael Merkenschlager

Matthias Michael Merkenschlager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells
    Patent number: 9314485
    Abstract: The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PI3K inhibitors, PI3K inhibitors for particular uses, and kits.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 19, 2016
    Assignee: MEDICAL RESEARCH COUNCIL
    Inventor: Matthias Michael Merkenschlager
  • USE OF PI3K M-TOR AND AKT INHIBITORS TO INDUCE FOXP3 EXPRESSION AND GENERATE REGULATORY T CELLS
    Publication number: 20150147304
    Abstract: The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PI3K inhibitors, PI3K inhibitors for particular uses, and kits.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 28, 2015
    Inventor: Matthias Michael Merkenschlager
  • Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells
    Publication number: 20100034786
    Abstract: The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits.
    Type: Application
    Filed: December 13, 2007
    Publication date: February 11, 2010
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventor: Matthias Michael Merkenschlager